Corton Capital Inc. Allogene Therapeutics, Inc. Transaction History

Corton Capital Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$3.17 - $5.96 $44,243 - $83,183	-13,957 Reduced 52.5%	12,628 $40,000
Q2 2023 Aug 14, 2023	SELL	$4.53 - $6.74 $29,739 - $44,248	-6,565 Reduced 19.8%	26,585 $132,000
Q1 2023 May 15, 2023	SELL	$4.92 - $8.21 $4,713 - $7,865	-958 Reduced 2.81%	33,150 $163,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $64,023 - $126,565	11,392 Added 50.15%	34,108 $214,000
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $119,918 - $200,793	-11,620 Reduced 33.84%	22,716 $245,000
Q2 2022 Aug 15, 2022	BUY	$6.78 - $12.28 $81,631 - $147,851	12,040 Added 54.0%	34,336 $391,000
Q1 2022 May 16, 2022	SELL	$7.65 - $15.29 $30,944 - $61,848	-4,045 Reduced 15.36%	22,296 $203,000
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $345,857 - $645,881	26,341 New	26,341 $393,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Corton Capital Inc. with notifications on news.